VOR BIOPHARMA DL-,0001

Vor Bio announced at the Wells Fargo conference that it has completed patient recruitment for the global Phase III study of telitacicept; evaluation of the 24‑week data is expected in spring 2027. Phase II data from China showed a 5.7‑point improvement in the MG‑ADL score, but management warns of a possible compression of the effect due to higher placebo responses globally and sees competition from FcRn therapies. Telitacicept is positioned as an upstream BAFF/APRIL agent with broader antibody effects and showed no hypogammaglobulinemia‑related discontinuation signal in about 3,000 treated patients. Other programs include a rapidly recruiting Sjögren’s study and a planned study for ocular MG in H1 2027; formulation optimizations are intended to reduce dosing frequency. » Plus sur de.investing.com

Vor Bio has appointed David Zaccardelli to its board of directors. Zaccardelli was most recently CEO of Verona Pharma until its acquisition by Merck in October 2025; there he led Phase‑3 programs to completion, secured FDA approval for Ohtuvyre and raised over $1 billion in capital. He previously served as CEO of Dova Pharmaceuticals and held leadership roles at United Therapeutics. With the appointment, Andrew Levin will leave the board. Vor Bio is a clinical-stage biotechnology company advancing telitacicept in global Phase‑3 trials, is approved in China for multiple indications, is valued at $1.1 billion and shows a high liquidity ratio (Current Ratio 31.15) according to analysis; the stock has risen 48% over the past six months and 54% year-to-date. » Plus sur de.investing.com

Vor Bio announced that the TELIGAN phase-3 data on telitacicept in IgA nephropathy, published in the New England Journal of Medicine, showed a marked reduction in proteinuria. At week 39 the 24-hour urine protein-to-creatinine ratio fell by 58.9% versus baseline compared with 8.8% on placebo (relative difference 55.0%). eGFR remained stable with telitacicept (-1.0% vs -7.7% with placebo) and serious adverse events were less frequent than with placebo. Telitacicept is already approved in China for several autoimmune diseases and Vor Bio is advancing additional global phase-3 studies. » Plus sur de.investing.com